专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20170224739A1 PLACENTAL STEM CELLS DERIVED FROM POST-PARTUM MAMMALIAN PLACENTA, AND USES AND METHODS OF TREATMENT USING SAID CELLS 审中-公开
公开(公告)号：US20170224739A1
公开(公告)日：2017-08-10
申请号：US15267695
申请日：2016-09-16
申请人： Anthrogenesis Corporation
发明人： Robert J. Hariri
IPC分类号： A61K35/50 , C12N5/073 , A61K35/51 , A61K35/545 , A61K35/28
CPC分类号： A61K35/50 , A61K35/28 , A61K35/51 , A61K35/545 , A61K2035/124 , C12N5/0605
摘要： The present invention provides compositions and methods of using placental stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The placental stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the placental stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The placental stem cells and the mixed populations of placental stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

2. 发明授权

US09539288B2 Immunomodulation using placental stem cells 有权
标题翻译：使用胎盘干细胞进行免疫调节
公开(公告)号：US09539288B2
公开(公告)日：2017-01-10
申请号：US14520934
申请日：2014-10-22
申请人： ANTHROGENESIS CORPORATION
发明人： Casper Paludan , James W. Edinger , Ryhor Harbacheuski , RoseAnn Murray , Robert J. Hariri
IPC分类号： A61K35/50 , C12N5/06 , C12N5/073 , C12N5/0775
CPC分类号： A61K35/50 , C12N5/0605 , C12N5/0668 , C12N2502/11
摘要： The present invention provides methods of immunomodulation using placental stem cells and placental stem cell populations. The invention also provides methods of producing and selecting placental cells and cell populations on the basis of immunomodulation, and compositions comprising such cells and cell populations.
摘要翻译：本发明提供使用胎盘干细胞和胎盘干细胞群进行免疫调节的方法。本发明还提供了在免疫调节的基础上产生和选择胎盘细胞和细胞群的方法，以及包含这种细胞和细胞群的组合物。

3. 发明申请

US20150313948A1 TREATING ORAL LESIONS USING PLACENTAL EXTRACELLULAR MATRIX 审中-公开
标题翻译：使用平面细胞基质处理口腔溃疡
公开(公告)号：US20150313948A1
公开(公告)日：2015-11-05
申请号：US14649990
申请日：2013-12-06
申请人： ANTHROGENESIS CORPORATION
发明人： Robert J. Hariri , Jodi P. Gurney , Mohit B. Bhatia , Wolfgang Hofgartner
IPC分类号： A61K35/50
CPC分类号： A61K35/50 , A61K35/12
摘要： Provided herein are uses of compositions comprising extracellular matrix (ECM) and compositions comprising ECM components in the treatment of non-dental oral lesions.
摘要翻译：本文提供包含细胞外基质（ECM）的组合物和包含ECM组分的组合物在治疗非牙科口腔损伤中的用途。

4. 发明申请

US20150306150A1 TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS 审中-公开
标题翻译：使用平面干细胞治疗骨相关癌
公开(公告)号：US20150306150A1
公开(公告)日：2015-10-29
申请号：US14792067
申请日：2015-07-06
申请人： ANTHROGENESIS CORPORATION
发明人： Xiaokui Zhang , Shmuel Yaccoby , Sascha Abramson , Robert J. Hariri
IPC分类号： A61K35/50 , A61K9/00 , C12N5/073
CPC分类号： A61K35/50 , A61K9/0019 , A61K31/4545 , A61K35/12 , C12N5/0605 , C12N2502/025 , C12N2502/1142 , C12N2502/30 , A61K2300/00
摘要： Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer.
摘要翻译：本文提供了使用胎盘细胞（例如本文所述的胎盘干细胞）和这种胎盘细胞群来抑制骨相关癌症例如多发性骨髓瘤或软骨肉瘤细胞的细胞增殖和生长的方法。本文还提供了治疗患有骨相关癌症细胞的个体的方法。

5. 发明申请

US20150017663A1 IDENTIFICATION OF ANTITUMOR COMPOUNDS USING PLACENTA 有权
标题翻译：使用PLACENTA鉴定抗肿瘤化合物
公开(公告)号：US20150017663A1
公开(公告)日：2015-01-15
申请号：US14380014
申请日：2013-02-22
申请人： Anthrogenesis Corporation
发明人： Robert J. Hariri , Mohit B. Bhatia , Qian Ye
IPC分类号： G01N33/50
CPC分类号： G01N33/5011 , G01N33/5088 , G01N2500/04 , G01N2500/20
摘要： Provided herein are methods of evaluating potential antitumor compounds, and thereby identifying antitumor compounds, using placenta or a portion thereof and tumor cells, and compositions for accomplishing the same. In one embodiment, provided herein is a method of determining whether a potential antitumor compound is effective against a plurality of tumor cells, comprising introducing a plurality of tumor cells to, e.g., into or onto, a mammalian placenta or portion thereof; contacting said plurality of tumor cells for a period of time with said antitumor compound; and determining whether said antitumor compound is effective against said tumor cells, wherein said antitumor compound is effective against said tumor cells if said antitumor compound over said period of time reduces the number of said tumor cells or reduces the growth rate of said tumor cells.
摘要翻译：本文提供了评估潜在的抗肿瘤化合物，从而使用胎盘或其一部分和肿瘤细胞鉴定抗肿瘤化合物的方法和用于实现其的组合物。在一个实施方案中，本文提供了确定潜在抗肿瘤化合物对多种肿瘤细胞有效的方法，包括将多种肿瘤细胞引入例如哺乳动物胎盘或其部分中或之上; 使所述多个肿瘤细胞与所述抗肿瘤化合物接触一段时间; 以及确定所述抗肿瘤化合物是否对所述肿瘤细胞有效，其中如果在所述时间段内所述抗肿瘤化合物减少所述肿瘤细胞的数量或降低所述肿瘤细胞的生长速率，则所述抗肿瘤化合物对所述肿瘤细胞有效。

6. 发明申请

US20140322175A1 Use Of Umbilical Cord Blood To Treat Individuals Having A Disease, Disorder Or Condition 审中-公开
标题翻译：使用脐带血治疗患有疾病，疾病或病症的个体
公开(公告)号：US20140322175A1
公开(公告)日：2014-10-30
申请号：US14085366
申请日：2013-11-20
申请人： Anthrogenesis Corporation
发明人： Robert J. Hariri
IPC分类号： A61K35/48
CPC分类号： A61K35/51 , A61K35/44 , A61K2035/124 , C12N5/0607
摘要： The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing.
摘要翻译：本发明提供以高剂量使用脐带血和脐带血干细胞治疗各种病症，疾病和病症的方法。高剂量脐带血和脐带血干细胞具有多种用途和应用，包括但不限于用于移植和治疗和预防疾病的治疗用途以及诊断和研究用途。特别地，脐带血或脐带血干细胞以高剂量递送，例如每次治疗至少30亿个有核细胞，其中治疗可以包括单次或多次输注。本发明还提供了来自多个供体的脐带血或脐带血来源的干细胞的使用，而不需要HLA分型。

7. 发明授权

US09763983B2 Natural killer cells from placenta 有权
公开(公告)号：US09763983B2
公开(公告)日：2017-09-19
申请号：US14764873
申请日：2014-02-04
申请人： ANTHROGENESIS CORPORATION
发明人： Xiaokui Zhang , Robert J. Hariri , Vanessa Voskinarian-Berse , Lin Kang , Eric Law , Stewart Abbot
IPC分类号： A61K31/454 , A61K35/17 , C12N5/0783 , A61K35/12
CPC分类号： A61K35/17 , A61K31/454 , A61K2035/122 , C12N5/0646 , C12N2501/05
摘要： Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.

8. 发明申请

US20170007648A1 TREATMENT OF INFLAMMATORY DISEASES USING PLACENTAL STEM CELLS 审中-公开
标题翻译：使用普通干细胞治疗炎症性疾病
公开(公告)号：US20170007648A1
公开(公告)日：2017-01-12
申请号：US15271429
申请日：2016-09-21
申请人： ANTHROGENESIS CORPORATION
发明人： James W. Edinger , Robert J. Hariri , Jia-Lun Wang , Qian Ye , Herbert Faleck
IPC分类号： A61K35/50 , A61K45/06
CPC分类号： A61K35/50 , A61K35/644 , A61K38/21 , A61K45/06 , A61K2035/122 , C12N5/0605 , C12N2500/25 , C12N2500/36 , C12N2501/11 , C12N2501/135 , C12N2501/39 , A61K2300/00
摘要： Provided herein are methods of treatment of individuals having an immune-related disease, disorder or condition, for example, inflammatory bowel disease, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis, psoriasis, lupus erythematosus, diabetes, mycosis fungoides (Alibert-Bazin syndrome), or scleroderma using placental stem cells or umbilical cord stem cells.
摘要翻译：本文提供了治疗具有免疫相关疾病，病症或病症的个体的方法，例如炎性肠病，移植物抗宿主病，多发性硬化，类风湿性关节炎，银屑病，红斑狼疮，糖尿病，蕈样真菌病（Alibert -Bazin综合征）或使用胎盘干细胞或脐带干细胞的硬皮病。

9. 发明申请

US20160289634A1 METHOD OF COLLECTING PLACENTAL STEM CELLS 审中-公开
标题翻译：收集普通干细胞的方法
公开(公告)号：US20160289634A1
公开(公告)日：2016-10-06
申请号：US15177779
申请日：2016-06-09
申请人： Anthrogenesis Corporation
发明人： Robert J. Hariri
IPC分类号： C12N5/073 , A01N1/02 , A61M1/02
CPC分类号： C12N5/0605 , A01N1/021 , A61K35/12 , A61K35/50 , A61K48/00 , A61K2035/124 , A61M1/02 , A61M2202/0462 , A61M2210/1458 , A61M2210/1466 , C12M29/10 , C12M47/04 , C12N5/0603 , C12N5/0647 , C12N5/0668 , C12N2509/00 , C12N2510/02 , C12N2533/90
摘要： A method of collecting embryonic-like stem cells from a placenta which has been treated to remove residual cord blood by perfusing the drained placenta with an anticoagulant solution to flush out residual cells, collecting the residual cells and perfusion liquid from the drained placenta, and separating the embryonic-like cells from the residual cells and perfusion liquid. Exogenous cells can be propagated in the placental bioreactor and bioactive molecules collected therefrom.
摘要翻译：一种从胎盘收集胚胎样干细胞的方法，其已经通过用排泄的胎盘用抗凝血剂溶液灌注去除残留的脐带血来清除残留细胞，从排出的胎盘收集残留细胞和灌注液，并分离来自残留细胞和灌注液的胚胎样细胞。外源细胞可以在胎盘生物反应器中繁殖并从其中收集生物活性分子。

10. 发明申请

US20160287635A1 TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS 审中-公开
公开(公告)号：US20160287635A1
公开(公告)日：2016-10-06
申请号：US14942337
申请日：2015-11-16
申请人： ANTHROGENESIS CORPORATION
发明人： Robert J. Hariri , Mohammad A. Heidaran , Lin Kang , Neerav Dilip Padliya , Ajai Pal , Vanessa Voskinarian-Berse , Andrew Zeitlin , Xiaokui Zhang
IPC分类号： A61K35/17 , A61K35/50 , A61K45/06
CPC分类号： A61K35/17 , A61K35/50 , A61K45/06 , A61K2035/124 , A61P35/00 , C12N5/0646
摘要： Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式